4/17/2009

GlaxoSmithKline and Pfizer are forming a company to combine their HIV-drug businesses, hoping to gain a nearly 20% share of the $12.3 billion AIDS market that Gilead Sciences dominates. GSK will take control of 85% of the firm, which will own 11 medicines on the market and six experimental treatments.

Full Story:
Bloomberg

Related Summaries